TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update

Publikation

TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update

Wissenschaftlicher Artikel/Review - 31.07.2020

Vulliemoz Marianne, Brand Stephan, Juillerat Pascal, Mottet Christian, Ben-Horin Shomron, Michetti Pierre, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology

Zitation

Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion 2020; 101 Suppl 1:16-26.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Digestion 2020; 101 Suppl 1

Veröffentlichungsdatum

31.07.2020

eISSN (Online)

1421-9867

Seiten

16-26

Kurzbeschreibung/Zielsetzung

BACKGROUND
Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years.

SUMMARY
This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to "rapid step-up therapy" or "top-down therapy" according to disease severity and patients' characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30-50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator.